Intrauterine Devices Market Size & Share 2026-2035

Intrauterine Devices Market Size

The intrauterine devices market was valued at USD 4.96 billion in 2025, is expected to reach USD 5.47 billion in 2026, and is projected to grow at a 10.3% CAGR from 2026 to 2035, reaching USD 13.23 billion by 2035.

The intrauterine devices market is moving from a primarily access-led contraceptive category toward a more differentiated reproductive-health market. Public procurement continues to underpin unit demand in lower-income settings, while hormonal systems are increasing revenue intensity in markets where reimbursement, provider capacity, and therapeutic use support broader adoption.

Intrauterine Devices Market Trends, Growth Drivers & GMI Forecast Outlook

Demand is being shaped by a dual-track market: access programs are broadening device availability in underserved settings, while hormonal systems are increasing clinical and revenue depth in more mature markets. The outlook depends on whether procurement, training, and reimbursement systems can convert unmet need into sustained insertion capacity.

Key Drivers

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

The global access gap gives IUD suppliers a durable demand pool, but the commercial opportunity depends on service delivery rather than device availability alone. WHO identifies persistent barriers around information, access, and quality of care in family-planning services, reinforcing the importance of trained providers and reliable care pathways in converting latent demand into adoption ^{[1]World Health Organization. “Family planning/contraception.” who.int}.

Public procurement is the principal bridge between unmet need and device volumes in lower-income markets. Government programs, donor purchasing, and social-marketing channels can create repeatable demand for long-acting methods, although manufacturers remain exposed to tender timing, budget releases, and distribution execution. Guttmacher's analysis highlights the scale of the financing and delivery challenge facing reproductive-health systems in low- and middle-income countries ^{[2]Guttmacher Institute. “Adding It Up 2024: Investing in Sexual and Reproductive Health in Low- and Middle-Income Countries.” guttmacher.org}.

Technology is also changing the commercial logic of the category. Miudella's approval introduced a new copper-device design focused on flexibility and simplified insertion, while CooperSurgical's single-hand Paragard inserter targets workflow friction for clinicians ^{[3]PR Newswire. “FDA Approves MIUDELLA, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years from Sebela Women's Health Inc..” prnewswire.com [5]CooperSurgical. “CooperSurgical Launches Paragard Intrauterine Copper Contraceptive with New Single-Hand Inserter.” coopersurgical.com}. These developments matter because provider confidence and procedural convenience influence whether IUDs are offered routinely beyond specialist settings.

Key Restraints

*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.*

Funding constraints are especially consequential where IUD demand is dependent on public financing. Even when long-acting methods offer favorable value over their period of use, constrained budgets must also support staffing, counseling, distribution, and follow-up care. Guttmacher identifies these interconnected investment requirements as a continuing limitation on universal access to contraceptive services ^{[2]Guttmacher Institute. “Adding It Up 2024: Investing in Sexual and Reproductive Health in Low- and Middle-Income Countries.” guttmacher.org}.

Clinical tolerance remains a differentiator between product categories. Evidence from the low-dose copper IUD study indicates that bleeding and pain can still interrupt continuation, even as product design advances ^{[6]Contraception. “DOI 10.1016/j.contraception.2024.110771.” doi.org}. Where hormonal systems are reimbursed and clinically appropriate, this creates a pathway toward switching; where they are not accessible, discontinuation can reduce retention in long-acting contraception altogether.

Provider capability is a separate structural constraint. Required training, supervised experience, and product-specific certification can slow rollout outside established gynecology networks. The Miudella REMS requirement illustrates how safety and commercialization can be linked to documented provider readiness, a consideration that may be more difficult to address in rural and resource-constrained care systems ^{[3]PR Newswire. “FDA Approves MIUDELLA, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years from Sebela Women's Health Inc..” prnewswire.com}.

Intrauterine Devices Market Segment Analysis

By Product

Hormonal IUDs are projected to reach USD 9.93 billion by 2035 and held a 70.6% share in 2025. Their lead reflects a clinical proposition that extends beyond contraception. Levonorgestrel-releasing systems support treatment pathways for heavy menstrual bleeding and can be relevant in perimenopausal care, giving clinicians reasons to recommend the category across a wider set of patient needs. Product portfolios with varied hormone doses and device formats further support individualized prescribing.

Copper IUDs generated USD 1.45 billion in 2025 and are projected to hold a 24.9% share by 2035. Copper devices remain strategically important because they provide a hormone-free option and support cost-sensitive public procurement. Their market position will be influenced by whether product redesign can reduce procedural and tolerability barriers without sacrificing the affordability that sustains their role in public-sector channels.

By Age Band

The 35-39 years age band generated USD 1.19 billion in 2025 and is projected to hold a 24.5% share by 2035. This cohort sits at a point where completed or evolving family-planning decisions often favor methods with long duration and low maintenance. It also has substantial overlap with patients seeking menstrual-management benefits, helping preserve demand for hormonal systems alongside contraceptive use.

The 40-44 years age band is projected to reach USD 2.31 billion by 2035 and held a 17.0% share in 2025. Demand in this group is shaped by the intersection of contraception and perimenopausal care. Hormonal IUDs can fit clinical discussions around heavy menstrual bleeding and transition-stage reproductive health, enabling use cases that are not solely dependent on pregnancy prevention.

The 30-34 years age band held a 22.0% share in 2025 and is projected to reach USD 2.91 billion by 2035. For many patients in this group, IUD duration aligns with family-spacing decisions while preserving reversibility. Providers can position the method as an alternative to adherence-dependent options, particularly when patients seek reliable contraception without closing off future fertility choices.

The 25-29 years age band generated USD 919 million in 2025 and is projected to grow at an approximately 10.0% CAGR (2026-2035). Adoption in this group benefits from changing provider norms around eligibility for younger and nulliparous patients. Greater familiarity with long-acting reversible contraception in community and reproductive-health settings is likely to keep IUD consideration earlier in the method-selection process.

The 20-24 years age band generated USD 422 million in 2025 and is projected to hold an 8.0% share by 2035. Access depends heavily on counseling quality, affordability, and the availability of providers willing to insert IUDs for younger adults. Community-health and college-adjacent care settings can be influential channels because they reduce the practical barriers between interest and an actual procedure.

The 15-19 years age band is projected to reach USD 291 million by 2035 and held a 2.5% share in 2025. This segment is shaped more by policy, provider culture, confidentiality, and family-planning service access than by product availability alone. As clinical guidance continues to support eligibility irrespective of parity, adoption will depend on whether those recommendations are consistently implemented in adolescent care settings.

The 45+ years age band generated USD 372 million in 2025 and is projected to grow at an approximately 10.8% CAGR (2026-2035). The category's relevance for this population increasingly rests on therapeutic and perimenopausal pathways. Reimbursement policies and gynecological practice patterns will determine how far these use cases translate into routine adoption across mature healthcare markets.

By End Use

Hospitals generated USD 2.33 billion in 2025 and are projected to hold a 46.9% share by 2035. Hospitals retain an advantage where credentialing, procedural support, and referral pathways are concentrated. They are also important sites for public-program insertion in markets where specialist care is centralized, making the setting relevant to both premium hormonal use and volume-oriented procurement programs.

Gynecology clinics are projected to reach USD 5.09 billion by 2035 and are expected to grow at an approximately 10.4% CAGR (2026-2035). Clinic expansion reflects patient demand for specialist continuity and more convenient access than hospital outpatient departments may offer. As insertion systems become easier to use and provider training broadens, clinics can capture a larger share of routine placements while preserving a high-touch counseling model.

Community healthcare centers generated USD 747 million in 2025 and are projected to grow at an approximately 10.0% CAGR (2026-2035). These centers are a critical access route where specialist care is scarce or unaffordable. Their ability to expand IUD provision will depend on stocked supply chains, public reimbursement, and workforce training, particularly in settings where they are the first point of contact for reproductive-health services.

Intrauterine Devices Market Regional Analysis

North America Intrauterine Devices Market Analysis

The North America intrauterine devices market generated USD 2.81 billion in 2025 and held a 56.6% share in 2025. The region's scale is underpinned by premium hormonal IUD pricing, established provider infrastructure, and insurance-supported access. Its relative global position may moderate as emerging markets expand, but the clinical depth of the North American market supports continued high-value demand and ongoing product differentiation.

U.S.

The U.S. intrauterine devices market generated USD 2.52 billion in 2025 and is projected to reach USD 6.44 billion by 2035. The United States combines a substantial hormonal IUD revenue base with an established copper-IUD category and a growing emphasis on insertion innovation. Coverage policy, manufacturer-led education, and provider availability will remain central to whether demand translates evenly across community, primary-care, and specialist settings.

Canada

Canada is projected to reach USD 716 million by 2035 and accounted for a 10.0% share of North American revenue in 2025. Provincial coverage arrangements and sexual-health clinic networks support a comparatively stable environment for long-acting contraception. Future expansion will be influenced by the extent to which broader drug-coverage discussions improve access to hormonal systems beyond currently covered populations.

Europe Intrauterine Devices Market Analysis

Europe is projected to reach USD 3.16 billion by 2035 and held a 25.0% share in 2025. The region combines mature clinical practice with national reimbursement systems that often support both copper and hormonal options. Growth is likely to be steady rather than access-constrained, although country-level differences in coverage, provider availability, and private-sector participation will continue to shape product mix.

Germany

Germany generated USD 260 million in 2025 and is projected to reach USD 664 million by 2035. Germany's position reflects its developed gynecology infrastructure, broad contraceptive awareness, and the local strength of established hormonal-IUD brands. Reimbursement eligibility and physician practice patterns remain the key determinants of adoption across patient groups.

United Kingdom

The United Kingdom is projected to reach USD 633 million by 2035 and accounted for a 20.0% share of European revenue in 2025. NHS-supported contraception and specialist clinical guidance provide an institutional base for IUD adoption. The market's accessibility is reinforced by care pathways that can serve adolescents, nulliparous patients, and adults seeking long-acting methods through both sexual-health and general-practice channels.

France

France generated USD 223 million in 2025 and is projected to hold an 18.0% share of European revenue by 2035. National reimbursement and a long-established role for gynecological care support broad product availability. The market is positioned to sustain demand across both hormonal and copper systems, with provider familiarity reducing the access friction seen in less mature European markets.

Italy

Italy is projected to reach USD 475 million by 2035 and accounted for a 15.0% share of European revenue in 2025. Regional variation in healthcare access and provider availability has historically limited uniform adoption. Growth will depend on the ability of women's-health clinics and regional health systems to close gaps between northern urban markets and less-served areas.

Spain

Spain generated USD 161 million in 2025 and is projected to reach USD 411 million by 2035. Expanded contraceptive coverage and increasing provider awareness support the market's long-term trajectory. Hormonal IUDs are positioned to capture a significant portion of incremental revenue as therapeutic use becomes more integrated into routine gynecological practice.

Netherlands

The Netherlands is projected to reach USD 253 million by 2035 and accounted for an 8.0% share of European revenue in 2025. Preventive reproductive healthcare and comparatively liberal contraceptive practices provide a favorable base for IUD use. The market remains an important reference point for adoption patterns among younger patients and for the integration of long-acting methods into primary reproductive-health care.

Asia Pacific Intrauterine Devices Market Analysis

Asia Pacific generated USD 571 million in 2025 and is projected to grow at an approximately 11.7% CAGR (2026-2035). The region contains sharply different demand models, ranging from public-sector copper-IUD programs in large population markets to premium hormonal prescribing in higher-income countries. Manufacturers must balance volume-oriented procurement with country-specific regulatory, reimbursement, and provider-channel strategies.

China

China generated USD 200 million in 2025 and is projected to reach USD 633 million by 2035. The market is evolving from a legacy public-health orientation toward a more mixed model that includes private-pay demand for hormonal systems. Urban expansion, rising consumer choice, and changing family-planning preferences create opportunities for suppliers that can address both public and private channels.

India

India is projected to reach USD 411 million by 2035 and is expected to grow at an approximately 12.5% CAGR (2026-2035). Government distribution provides a large-volume foundation for copper IUDs, while urban private care supports an emerging hormonal-IUD opportunity. The market's potential depends on the ability to strengthen counseling, clinical training, and access beyond higher-income metropolitan areas.

Japan

Japan generated USD 103 million in 2025 and accounted for an 18.0% share of Asia Pacific revenue in 2025. The market is characterized by premium hormonal-IUD demand within a regulated healthcare environment. Therapeutic prescribing and growing recognition of menstrual-management applications can support further adoption, particularly as clinical familiarity broadens.

South Korea

South Korea is projected to reach USD 205 million by 2035 and accounted for a 12.1% share of Asia Pacific revenue in 2025. Private gynecology clinics play an influential role in IUD access and reinforce a premium product mix. Continued consumer awareness and high-quality reproductive-health infrastructure support the market, though growth remains tied to provider recommendation and out-of-pocket affordability.

Australia

Australia generated USD 46 million in 2025 and is projected to grow at an approximately 10.1% CAGR (2026-2035). Public subsidy for eligible hormonal IUD users reduces a key cost barrier, while growing primary-care awareness can expand access beyond specialist practices. Demand is increasingly supported by recognition of both contraceptive and therapeutic benefits.

Latin America Intrauterine Devices Market Analysis

Latin America is projected to reach USD 551 million by 2035 and held a 3.7% share in 2025. The region is at an earlier stage of long-acting contraceptive penetration than North America and Europe. Public procurement provides a copper-device base, while expanding private care in major cities creates a separate pathway for hormonal IUD revenue growth.

Brazil

Brazil generated USD 92 million in 2025 and is projected to reach USD 276 million by 2035. Brazil's public health system supports an established copper-IUD volume base, while private-sector gynecology is expanding the hormonal segment in urban markets. This dual-channel structure gives manufacturers a route to participate in both access-focused and premium demand.

Mexico

Mexico is projected to reach USD 193 million by 2035 and accounted for a 34.8% share of Latin American revenue in 2025. Social-security provision supports access to copper IUDs, while private providers serve a growing market for hormonal systems. Competitive success will require channel strategies that address institutional purchasing and private gynecology without treating them as interchangeable demand pools.

Argentina

Argentina generated USD 18 million in 2025 and is projected to grow at an approximately 11.8% CAGR (2026-2035). Public distribution programs support basic device access, while private-sector hormonal-IUD demand is centered in higher-income urban areas. The opportunity depends on maintaining supply continuity in a market where economic conditions can affect private-pay uptake.

Middle East & Africa Intrauterine Devices Market Analysis

Middle East & Africa generated USD 60 million in 2025 and is projected to grow at an approximately 17.2% CAGR (2026-2035). The region has a low penetration base but substantial latent demand, producing a high-growth outlook that is closely tied to service capacity. Donor-supported distribution is essential across much of sub-Saharan Africa, while Gulf markets offer a separate private-pay opportunity for premium systems.

Saudi Arabia

Saudi Arabia generated USD 21 million in 2025 and is projected to reach USD 109 million by 2035. Healthcare investment, changing family-formation patterns, and a developed private-provider base support the market's expansion. Demand for premium hormonal systems is likely to remain concentrated in urban care networks where specialist reproductive-health services are readily available.

UAE

The UAE is projected to reach USD 78 million by 2035 and accounted for a 25.0% share of Middle East & Africa revenue in 2025. A young expatriate population, high-quality private healthcare, and the country's role as a regional care hub support premium IUD demand. Product launches and specialist-service access can translate quickly into adoption in this comparatively concentrated healthcare market.

South Africa

South Africa generated USD 18 million in 2025 and is projected to grow at an approximately 17.9% CAGR (2026-2035). The country provides an important distribution and service-delivery base for southern Africa. Public family-planning programs create an access-oriented foundation, while improving private gynecology access in major urban provinces supports the gradual expansion of hormonal IUD use.

Rest of World Intrauterine Devices Market Analysis

Rest of World is projected to reach USD 331 million by 2035 and held a 2.0% share in 2025. This grouping includes underpenetrated markets where expanded family-planning coverage and better healthcare access can create incremental demand. Commercial progress will be uneven because regulatory readiness, clinical capacity, and procurement systems vary substantially across the included geographies.

Intrauterine Devices Market Share & Competitive Landscape

The intrauterine devices market share structure is moderately concentrated, with the five leading suppliers collectively holding approximately 49.5% of the market in 2025. Competitive intensity differs materially by product type: branded hormonal systems are concentrated around global platforms with established clinical evidence and distribution, while copper-IUD supply is more fragmented across public-tender, regional, and lower-cost manufacturers.

Bayer AG held approximately 29.9% of the market in 2025. Bayer's leadership is supported by the breadth of its hormonal-IUD portfolio and its established presence across major developed markets. Its competitive advantage rests on brand familiarity, provider education, and the ability to position products across contraception, menstrual management, and patient groups requiring different device formats.

AbbVie held approximately 8.5% of the market in 2025. AbbVie's position is centered on Liletta and a U.S.-oriented women's-health commercial infrastructure. The company is particularly relevant in access-sensitive channels where competitive pricing and relationships with public programs, community providers, and Medicaid-linked care can influence product selection.

CooperSurgical held approximately 6.2% of the market in 2025. CooperSurgical's Paragard franchise gives it a distinctive position in the U.S. copper-IUD market. Its single-hand inserter launch addresses a practical clinical barrier by simplifying placement workflow, a move that can strengthen the product's relevance in primary-care and community settings as well as specialist clinics ^{[5]CooperSurgical. “CooperSurgical Launches Paragard Intrauterine Copper Contraceptive with New Single-Hand Inserter.” coopersurgical.com}.

Medicines360 participates in the hormonal-IUD category through Liletta in the United States and Avibela in lower-resource markets. Its strategy links a domestic commercial platform with access-oriented partnerships designed to extend hormonal IUD availability in markets where affordability and procurement structure are decisive.

Eurogine competes primarily through copper and hormonal IUD portfolios serving European and public-procurement channels. Its position reflects the continued importance of competitively priced devices in tenders where supply reliability, regulatory compliance, and unit economics can carry more weight than branded differentiation. Other suppliers, including DKT, GIMA, GYNO CARE, HLL Lifecare Limited, Meril, MONA LISA, PREGNA, Prosan, Sebela Pharmaceuticals, and SMB, reinforce competitive diversity across regional and public-sector markets.

Recent Industry Developments

Organon - Global Licensing Agreement for MIUDELLA® (February 2026). Organon announced an exclusive global licensing agreement for MIUDELLA, Sebela Pharmaceuticals' hormone-free copper IUD. The agreement expands Organon's women's-health portfolio and signals continuing strategic interest in copper-device innovation, subject to the stated regulatory and transaction conditions ^{[4]Organon. “Organon Enters into Agreement to License MIUDELLA, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device.” businesswire.com}.

Sebela Pharmaceuticals - MIUDELLA® FDA Approval (February 2025). The FDA approved MIUDELLA as the first hormone-free copper intrauterine system cleared in the United States in more than four decades. Its flexible nitinol frame and preloaded inserter were designed to address insertion-related barriers in the copper-IUD category, while commercialization is subject to a provider-training REMS program ^{[3]PR Newswire. “FDA Approves MIUDELLA, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years from Sebela Women's Health Inc..” prnewswire.com}.